Evaulation of the clinical efficacy and safety of the combined administration of Imidafenacin and Tamsulosin in BPH patients (in which OAB symptoms remain) who did not respond to alpha-1 blocker monotherapy.
- Conditions
- Overactive bladder
- Registration Number
- JPRN-UMIN000005012
- Lead Sponsor
- Department of Urology, University of Yamanashi, School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- Male
- Target Recruitment
- 300
Not provided
(1)Patients who have administered prohibited substances or who have administered prohibited therapy in the 8 weeks prior to the 1st period (2)Patients who changed the dosage or usage of a restricted medicine in the specified period before the 1st period (3)Patients with anuresis (4)Patients with prostate cancer, neurogenic bladder, urethra stricture, chronic prostatitis, symptomatic urinary tract infection, urinary tract stones and interstitial cystitis (5)Patients with serious cardiac disorder, serious liver dysfunction and serious kidney dysfunction (6)Patients with orthostatic hypotension (7)Patients with pyloristenosis,constriction of dodecadactylon, construction of enteron and adynamic ileus (8)Patients with deterioration of enterokinesis (9)Patients with angle-closure glaucoma (10) Patients with myasthenia gravis. (11) Patients in which it has been confirmed that Qmax is less than 5mL/s. (12)Patients with Polyuria. (13)Any other patients who are regarded as unsuitable for this study by the investigator
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change of total OABSS score
- Secondary Outcome Measures
Name Time Method